Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial

Katja Weisel,Meletios Dimopoulos,Albert Oriol,Meral Beksac, Frederick Schjesvold, Anna Marina Liberati,Jindriska Lindsay,Darrell White, Jesus San-Miguel, Philippe Moreau,Larry D. Anderson, Alessandra Lorocca,Pawel Robak,Prisca Vogel,Ruiyun Jiang,Lara Grote,Teresa Peluso,Paul Richardson

ONCOLOGY RESEARCH AND TREATMENT(2022)

引用 0|浏览13
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要